Project Grant R37CA285289
Award Date
7/1/24
Completion Date
6/30/29
Dollars Obligated
$483K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This $532,970 Project Grant award, provided by the National Cancer Institute under the Cancer Treatment Research federal grant program (CFDA 93.395), supports research to define the key cell-intrinsic features and cell interactions of anti-tumor CD4 T cells that promote anti-tumor immunity and enhance responses to PD-1 targeted immunotherapy. The 5-year study, beginning April 1, 2025, will use an autochthonous immunogenic mouse model of liver cancer to: 1) investigate the transcriptional...
This $588,426 Project Grant award, provided by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), aims to investigate how transcription factors efficiently locate and bind to specific DNA binding sites within the crowded nucleus of living cells. The project will employ advanced microscopy techniques to precisely track the 3D diffusion, DNA interactions, and target site discrimination of transcription factors involved in...
The National Cancer Institute (NCI) awarded a $147,486 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Baylor College of Medicine to support a research project titled "A Novel Immune Tolerization Strategy for Investigating the Trade-offs Between Oncogene Pathogenicity and Immunogenicity." The project aims to develop a novel immune tolerization strategy called RECON to uncouple an oncogene's pathogenic potential from its immunogenic properties, enabling the...
The President and Fellows of Harvard College, doing business as Harvard Medical School, was awarded a $127,049 Project Grant by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) to investigate the functional and spatial properties of tumor-specific, tumor-infiltrating CD8 T cells. The key products and services to be delivered under this award include: Generating patient-derived xenograft (PDX) murine models of 3 melanoma patient tumors to test the required diversity of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $234,919 to Yale University from September 1, 2024 to August 31, 2027 to develop a novel approach for multiplexed and high-sensitivity detection of gene expression using CRISPR-mediated transcriptional activation. The project aims to fluorescently report the transcriptional activity of 9 or more cytokines simultaneously, dynamically, and in situ in tissues. This will address...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to understand the role of stress granules in T cell exhaustion and improve the efficacy of CAR-T cell therapies for treating solid tumors. The $415,257 award to The Methodist Hospital Research Institute (HMRI) will fund a 2-year project investigating how modulating the stress granule regulatory network, specifically targeting the G3BP1 protein, can enhance CAR-T cell...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $604,627 to the Trustees of Dartmouth College to conduct research aimed at understanding and engineering durable chimeric antigen receptor (CAR) T-cell therapies for solid tumor cancers. The key focus is on deconvolving the heterogeneity of CAR T-cell populations to identify strategies for programming optimal effector and memory T-cell responses. The research will utilize...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), provides $626,534 over a 5-year period from December 1, 2024 to November 30, 2029 to The Medical University of South Carolina (MUSC) to support research aimed at understanding how transient endoplasmic reticulum (ER) stress responses can be leveraged to improve the anti-tumor function of T cells. The key objectives are to: 1) Determine how ER stress-induced...
This $693,880 Project Grant award from the National Cancer Institute's Cancer Treatment Research Program (CFDA 93.395) supports the Fred Hutchinson Cancer Center in Seattle, Washington to develop a novel cancer immunotherapy approach using engineered CD4+ T cells. The research aims to overcome treatment resistance in solid tumors, such as melanoma, by leveraging CD4+ T cells to activate other immune cells in the tumor microenvironment. The researchers plan to isolate and expand tumor-specific...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under CFDA 93.859 Biomedical Research and Research Training program, supports research to characterize the tumor immune microenvironment (TIME) of lung and liver metastases in triple negative breast cancer (TNBC). The primary objectives are to: Spatially profile the TIME of lung and liver metastases following treatment with anti-CSF1R, chemotherapy, and anti-PD1 to identify resistance mechanisms and...